Reviewer’s report

Title: Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in nonsmall cell lung cancer patients (HANSHIN 0316)

Version: 0 Date: 09 Jun 2018

Reviewer: Raheleh Roudi

Reviewer's report:

In the current survey, the Tachihara et al analyzed the Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients.

The authors need to consider some points;

1) The abbreviations for PR and SD should be added to abstract.

2) The complete list of irAEs in lung cancer patients treated with anti-PD-1/PD-L1 antibodies has been evaluated in a study by Xiaoying Sun etal, 2017. This reference need to include in this section.

3) Other treatment regimens in the patients need to include in the manuscript.

4) The results section has been categorized in three parts;

   a) Patients characteristics

   b) Data related to adverse effects

   c) Data related to survival

5) Resolution of the images needs to improve.
6) The immunotherapy for lung cancer needs to expand in the discussion with more recent studies; including Jianwei Zhu et al, 2017 and Nicholas L. Syn et al, 2018.

7) The conclusion needs to be elaborated.

**Are the methods appropriate and well described?**
If not, please specify what is required in your comments to the authors.

Yes

**Does the work include the necessary controls?**
If not, please specify which controls are required in your comments to the authors.

Yes

**Are the conclusions drawn adequately supported by the data shown?**
If not, please explain in your comments to the authors.

No

**Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?**
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

**Quality of written English**
Please indicate the quality of language in the manuscript:

Acceptable
Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal